Documents

Displaying 1 - 20 of 218 results
 
Collapse Filters
 
Expand Filters         +
April 9, 2019

Greg Cherundolo Unprecendented Migration at the U.S. Southern Border: Perspectives from the Frontline

Greg Cherundolo Chief of Operations Office of Global Enforcement Drug Enforcement Administration U.S. Department of Justice before the United States Senate Homeland Security and Governmental Affairs Committee

April 1, 2019

SFL8 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of April 1, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration

April 1, 2019

SFL7 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of April 1, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration

April 1, 2019

SFL6 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of April 1, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 1, 2019

SFL5 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of April 1, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 1, 2019

SFL4 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of April 1, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 1, 2019

SFL3 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of April 1, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 1, 2019

SFL2 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of April 1, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

 

April 1, 2019

SFL1 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of April 1, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

 

April 1, 2019

Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of April 1, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

February 21, 2019

Acting Administrator Uttam Dhillon, Museum of Natural History and Science

Acting Administrator Uttam Dhillon at the Drugs: Cost and Consequences Press Conference, Museum of Natural History and Science, Albuquerque, New Mexico

February 19, 2019

Athletes and Opioids Poster

What is prescription pain reliever misuse? As defined by the National Survey on Drug Use and Health, it’s “use without a prescription of one’s own or use at a higher dosage or more often than prescribed.” Prescription opioid addiction – stemming from misuse – has hit the nation hard in recent years. Unfortunately, high school student-athletes can be especially vulnerable to prescription painkiller misuse. This poster encourages teens, parents and other caregivers, and educators to know the risks around misusing pain pills.

February 5, 2019

Acting Administrator Uttam Dhillon, University of South Carolina-Aiken

Acting Administrator Uttam Dhillon at the University of South Carolina-Aiken, Chancellor’s Signature Speaker Series Aiken, South Carolina

December 12, 2018

Paul E. Knierim Narcos: Transnational Cartels and Border Security

Statement of Paul E. Knierim Deputy Chief of Operations, Office of Global Enforcement Drug Enforcement Administration Before the Subcommittee on Border Security and Immigration Committee on the Judiciary United States Senate

October 29, 2018

Heroin Domestic Monitor Report

The DEA Heroin Domestic Monitor Program (HDMP) is a retail-level heroin purchase program that provides data analysis about the geographic source of heroin along with price, purity, adulterants, and diluents sold at the street-level in 27 U.S. cities. The data in this report is from 2016.

October 18, 2018

Prescription For Disaster

Increasing numbers of teens are using prescription and over-the-counter medications to get high. Many parents and caregivers don’t know enough about this problem, and many teens don’t understand the dangers. Prescription for Disaster: How Teens Abuse Medicine is a guide that helps parents and caregivers understand and identify the medications teens are abusing. An invaluable resource for parents and caregivers, Prescription for Disaster: How Teens Abuse Medicine presents prescription drug basics, includes information about commonly abused prescription drugs, lists steps parents and caregivers can take to keep their teens drug free, and more.

October 17, 2018

Acting Administrator Uttam Dhillon, DEA Headquarters Red Ribbon Rally

Acting Administrator Uttam Dhillon, delivers a speech during the DEA Headquarters Red Ribbon Rally.

October 15, 2018

Opioid Threat in Pennsylvania

Crafting initiatives and strategies to address opioid supply, demand, and misuse requires timely and actionable information and data, which this report endeavors to provide. This report presents a comprehensive assessment of the opioid crisis in Pennsylvania, through collection and analysis of supply and demand indicators and intelligence, as well as detailed county level analysis of multiple opioid misuse data sources.

October 15, 2018

Heroin Signature Report

The Drug Enforcement Administration’s Heroin Signature Program (HSP) analyzed several hundred wholesale-level heroin samples in 2016 to identify the geographic area where the samples were manufactured (Mexico, South America [SA], Southwest Asia [SWA], or Southeast Asia [SEA]).

October 15, 2018

Greater New Orleans Situational Drug Report

The purpose of the Greater New Orleans Situational Drug Report is to identify current and emerging drug trends within the New Orleans metropolitan area as well as to deliver accurate and timely strategic intelligence to assist drug treatment and prevention organizations in the development of drug prevention and mitigation strategies. This assessment provides an overview of the region’s primary drug threats.

DEA US Badge
United States Drug Enforcement Administration DEA.gov is an official site of the U.S. Department of Justice